Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
03. Januar 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12. Dezember 2023 07:00 ET
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
29. November 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
28. November 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
15. November 2023 08:15 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
09. November 2023 16:05 ET
|
Athira Pharma, Inc.
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments...
Athira Pharma to Participate in Jefferies London Healthcare Conference
08. November 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
05. Oktober 2023 16:30 ET
|
Athira Pharma, Inc.
Athira Pharma presents new preclinical data on ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS).
Athira Pharma to Participate in Upcoming October Conferences
28. September 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
19. September 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...